Rabbit uterus contains type I and I1 oestrogen binding sites in the cytosol, and nuclear fractions. Oestrogen-stimulated increase in uterine weight was inhibited by concurrent treatment with progesterone or danazol. Oestrogen-induced type I binding sites were decreased by progesterone and to a lesser extent by danazol, while oestrogen-induced type I1 sites were decreased almost equally in the two groups. Neither progesterone nor danazol alone caused any detectable changes in uterine weight. These findings may suggest that the anti-oestrogenic effect on uterine weight is more correlated with the change in type I1 binding sites of oestrogen than that in type I sites. Thus, danazol may exert anti-oestrogenic actions through a pathway independent from that of progesterone.
Danazol is widely used for the treatment of pelvic endometriosis. The therapeutic effects may be in part derived from its anti-oestrogenic activity (or progestational activity); the growth of implanted endometriosis is stimulated by oestrogens and inhibited by progesterone.' Oestrogen binds to its specific receptor and exerts its specific functions. Two kinds of oestradiol-17 ( 3 (E,) binding sites, namely type I and I1 sites, have been investigated by Clark and Peck., This situation prompted us to compare the effects of danazol and progesterone on these binding sites in the rabbit uterus and on the oestrogen-stimulated increase in uterine weight.
MATERIALS AND METHODS
Immature white rabbits were treated with E, (10 &day) alone, or with E, and either danazol (1 7a-pregna-2, 4-dien-U)-yno(2,3-d) isoxazol-17-01, 16 mg/day) or progesterone (1 mg/day) in sesame oil subcutaneously. After 14 days, the rabbits were killed and the uteri were removed. The cytosolic fraction, and the KC1-extractable and KC1-unextractable nuclear fractions were prepared essentially as previously described3 and submitted 
uteri. Cytosol was incubated with various concentrations of ['HI estradiol (E,) in the presence of either a 200-fold molar excess of dihydrotestosterone (DHT) ( A ~ A ) or a 200-fold molar excess of DHT and diethylstilbestrol (DES) (au). Specific binding was obtained by subtracting the binding of ['HI E, binding in the presence of both DHT and DES from the binding of ['HI E2 binding in the presence of DHT. Each point represents the mean of three determinations.
I Uterine weight E, Type I sites E, Type I 1 sites I I (Boston, USA) . Steroids and all other chemicals were of reagent grade.
FIGURE 2. Effects of progesferone and danazol on the weight and the estradiol binding sites in rabbit uterus stimulated by estradiol. Rabbits were treated with estradiol ( E j , E, and progesterone (P

RESULTS
E, stimulated rabbit uterine growth. Figure 2 shows the effects of progesterone and danazol on the E,-induced increases in uterine weight and also on the E2 binding sites in the uterus.
Concurrent treatment with progesterone or danazol inhibited the E,-stimulated uterine growth similarly, while their effects on E2 binding sites were in part different. E,-induced type I sites were decreasd by progesterone and to the lesser extent by danazol, whereas type I1 sites were decreased almost equally in the two groups.
Progesterone or danazol alone showed no detectable changes in uterine weight. These findings suggested that the anti-oestrogenic effect on uterine weight correlates better with the changes in type I1 E, binding sites than with those in type I sites. Thereby separate mechanisms may mediate the anti-oestrogenic actions of progesterone and danazol.
DISCUSSION
Oestrogens have multiple actions in the uterus, which are thought to be primarily regulated via binding to a specific receptor. The tissue concentration of oestrogen in vivo may increase over the physiological concentration, and binding sites for oestrogen have been found in the uterus. Uterine cytosol contains two types of specific oestrogen-binding macromolecules. Type I sites conform to the characteristics of the high affinity and low capacity oestrogen receptor. The type I sites exist in several forms, which may represent subunits and/or different states of the receptor. The other (type 11) sites exert a lower affinity and greater capacity for oestrogen than type I sites. Oestrogen increases the level of the type I1 site,5 which may be involved in the mechanism by which oestrogen stimulates uterine growth.
Progesterone is anti-oestrogenic, through its inhibition of oestrogen receptor replenishment.2
The oestrogen-induced stimulation of type I1 sites is reported as being inhibited by progesterone, and this correlates with an inhibition
